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http://dx.doi.org/10.1016/j.ccell.2015.06.005SUMMARYA variety of cancers depend on JAK2 signaling, including the high-risk subset of B cell acute lymphoblastic
leukemias (B-ALLs) withCRLF2 rearrangements. Type I JAK2 inhibitors induce paradoxical JAK2 hyperphos-
phorylation in these leukemias and have limited activity. To improve the efficacy of JAK2 inhibition in B-ALL,
we developed the type II inhibitor CHZ868, which stabilizes JAK2 in an inactive conformation. CHZ868
potently suppressed the growth of CRLF2-rearranged human B-ALL cells, abrogated JAK2 signaling, and
improved survival in mice with human or murine B-ALL. CHZ868 and dexamethasone synergistically induced
apoptosis in JAK2-dependent B-ALLs and further improved in vivo survival compared to CHZ868 alone.
These data support the testing of type II JAK2 inhibition in patients with JAK2-dependent leukemias and
other disorders.INTRODUCTION
Outcomes for most children with B cell acute lymphoblastic leu-
kemia (B-ALL) have drastically improved over the past 30 years
through the iterative refinement of multi-agent chemotherapy
regimens (Pui et al., 2004). However, the 15%–30% of cases
that harbor Philadelphia chromosome (Ph)-like transcriptional
signatures but lack BCR-ABL rearrangements continue to have
a poor prognosis (Mullighan et al., 2009b; Roberts et al., 2012,
2014).Significance
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The most common rearrangements in Ph-like B-ALL, occur-
ring in approximately 50% of cases, are translocations and
intrachromosomal deletions that result in overexpression of the
CRLF2 cytokine receptor (Hertzberg et al., 2010; Mullighan
et al., 2009a; Russell et al., 2009; Yoda et al., 2010). Unlike
signaling downstream of EPOR or MPL, CRLF2 signaling is
believed to involve heterodimerization of CRLF2 with the IL7Ra
subunit and transduction through JAK2 (interacting with
CRLF2) and JAK1 (interacting with IL7Ra) (Sessa et al., 2013;
Wohlmann et al., 2010).
Overexpression of CRLF2 alone is not sufficient to constitu-
tively activate downstream signaling in model systems. CRLF2-
rearranged B-ALLs frequently harbor a second genetic alteration
within the CRLF2 signaling cascade, most commonly in exon 16
of JAK2 (Hertzberg et al., 2010; Mesbah et al., 2012; Mullighan
et al., 2009a; Russell et al., 2009). Additional cases have alter-
ations elsewhere in JAK2, in CRLF2 itself, JAK1, IL7R, SH2B3,
or TSLP that activate JAK2/STAT5 signaling via CRLF2 (Roberts
et al., 2014; Shochat et al., 2011, 2014; Yoda et al., 2010).
We previously reported that our model systems of B-ALL
cells dependent on JAK2 signaling downstream of CRLF2 are
refractory to type I JAK2 inhibitors like ruxolitinib (Weigert
et al., 2012), which target the ATP-binding pocket and stabilize
JAK2 in the active confirmation. In these cells, type I inhibitors
induce paradoxical JAK2 hyperphosphorylation. The Levine lab-
oratory reported that type I JAK2 inhibitors can induce a state of
persistent JAK2 signaling in EPOR- or MPL-expressing myeloid
cells that involves heterodimerization and trans-phosphorylation
of JAK2 by JAK1 or TYK2 (Koppikar et al., 2012). Importantly,
persistent JAK2 signaling in myeloid cells was abrogated by
treatment with the type II JAK2 inhibitor BBT594 (Koppikar
et al., 2012), which stabilizes JAK2 in an inactive confirmation
and blunts activation loop phosphorylation (Andraos et al.,
2012). BBT594 (Figure 1A) was initially developed as an inhibitor
of BCR-ABL T315I, but was found to also inhibit JAK2 by stabi-
lizing the inactive conformation (Andraos et al., 2012). BBT594
has limitations in potency and selectivity for JAK2 as well as
pharmacokinetic properties that preclude in vivo use. Thus, we
developed another type II inhibitor to further explore the potential
of type II JAK2 inhibition in B-ALL.
RESULTS
The Type II JAK2 Inhibitor CHZ868 Blocks JAK2
Signaling In Vitro and In Vivo
We launched a discovery program to identify type II JAK2 inhib-
itors with improved potency, selectivity, and physicochemical
properties. Mining of the Novartis database for compounds con-
taining structural motifs canonical for type II kinase inhibition,
followed by a cellular screening campaign using JAK2 V617F
mutant SET-2 cells to identify compounds that suppress phos-
phorylation of both JAK2 and STAT5, revealed arylamino-benz-
imidazoles, originally described as RAF kinase inhibitors (Shiels
et al., 2011), as an attractive starting point for an optimization
program. Medicinal chemistry efforts, driven by property and
protein structure based considerations, led to the discovery of
CHZ868 (Figure 1A).
In terms of physicochemical and pharmacokinetic properties,
CHZ868 is characterized by high passive permeability, good30 Cancer Cell 28, 29–41, July 13, 2015 ª2015 Elsevier Inc.metabolic stability, and lowwater solubility, as well as by moder-
ate blood clearance and good oral bioavailability (Table S1),
making it suitable for in vivo use. Consistent with a type II binding
mode, CHZ868 showed modest inhibitory activity in enzymatic
assays with activated (phosphorylated) JAK2 kinase, but
demonstrated excellent potency in JAK2-driven cellular assays
(Figure 1B). Importantly, JAK2 inhibitory activity of CHZ868
is 3- to 9-fold improved over BBT594, whereas some of the
BBT594 off-target activities, such as BCR-ABL, RET, and FLT3
inhibition, are significantly reduced (Figure 1B).
Broader CHZ868 in vitro kinase selectivity was assessed in a
panel consisting of over 400 kinases. At 100 nM, CHZ868 had
activity against 26 kinases, including JAK2 and TYK2 (Figures
S1A and S1B). As the kinome panel is predominantly composed
of activated (i.e., phosphorylated) kinases, profiling of type II in-
hibitors may have limitations for selectivity predictions, given
their preferential binding to inactive kinase conformations.
Thus, CHZ868 kinome panel hits were followed up in available
cell-based kinase selectivity assays. In the cellular setting, low
nanomolar activity against KIT, as well as PDGFR and VEGFR
family kinases, was substantiated, whereas activity against
ABL, BRAF, and RET was not corroborated (Figure S1B).
To determine the appropriate dose and schedule of CHZ868
in vivo, we utilized a murine model of polycythemia induced by
exogenous erythropoietin (Baffert et al., 2010). Control mice
receiving recombinant human erythropoietin (rhEpo) exhibited
a marked induction of pSTAT5 in the spleen and bone marrow
(Figures S1C and S1D). At an oral dose of 30 mg/kg, CHZ868
completely blocked the induction of pSTAT5 by rhEpo in
mice when administered 2 hr prior to sampling. At that time
point, the concentration of CHZ868 within the spleen was
4.3 nmol/g (Figure S1C). By 6 hr after CHZ868 dosing, the drug
level within the spleen was <1 nmol/g, consistent with the blood
t1/2 in mice of 1 hr (Table S1). Despite the kinetics of CHZ868
elimination, the ability of rhEpo to induce pSTAT5 in the spleen
and bone marrow remained attenuated for 48–72 hr (Figures
S1C and S1D).
Next, we treated BALB/c mice with daily injections of either
saline or rhEpo for 4 consecutive days. Mice also received either
vehicle or CHZ868 and all animals were sacrificed on day 5.
Treatment with CHZ868 at 30 mg/kg/day completely blocked
splenomegaly induced by rhEpo (Figure S1E). The same dose
of CHZ868 also blocked the increase in reticulocyte count
induced by rhEpo but did not affect white blood cell (WBC) count
(Figure S1F). Importantly, treatment of wild-type mice with
CHZ868 at 30 mg/kg/day for >6 weeks had no significant effects
on body weight, peripheral blood cell counts, bone marrow
cellularity, or the fractions of hematopoietic progenitors in the
bone marrow (Figures S1G–S1M). Mice receiving CHZ868 had
trends toward reduced spleen weights and elevated serum
erythropoietin levels (Figures S1N and S1O), which are expected
on-target effects. Taken together, these results show that
CHZ868 30 mg/kg/day potently blocks JAK2 signaling with min-
imal toxicity in vivo.
Binding Mode Model of CHZ868 to JAK2
Our binding mode model of CHZ868 to JAK2 shares most of the
characteristics described by the X-ray crystallographic structure
of BBT594 binding to JAK2 (PDB: 3UGC) (Andraos et al., 2012).
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Figure 1. The Type II JAK2 Inhibitor CHZ868 Blocks JAK2 Signaling In Vitro and In Vivo
(A) Chemical structures of type I and II JAK2 inhibitors.
(B) IC50 values for CHZ868 and BBT594 in enzymatic and cell-based assays.
(C) Binding mode model of CHZ868 to JAK2. Ribbon representation of the JAK2 kinase domain with CHZ868 illustrated as a stick model. Amino acid side chains
interacting with the inhibitor are shown in green. Polar contacts between the protein and the inhibitor are highlighted with dotted purple lines.
(D) IC50 values for type I and II JAK2 inhibitors in Ba/F3 cells expressing the indicated proteins in the absence of cytokines, except where ‘‘+TSLP’’ indicates 1 nM
TSLP. Error bars represent SEM.
(E) Immunoblotting against the indicated targets using lysates from Ba/F3-CRLF2/JAK2 R683G cells exposed to the indicated concentrations of JAK2
inhibitors for 2 hr.
See also Figure S1 and Table S1.CHZ868 is thought to engage with the hinge region of JAK2
through two H-bonds, formed between the amino-pyridine of
CHZ868 and the backbone-NH/CO of L932, while the pyridine
is occupying the adenine pocket of the ATP binding site (Fig-
ure 1C). Archetypal for a type II bindingmode, the acceptor nitro-
gen of the 2-amino benzimidazole core is expected to interact
with the backbone NH of D994, whereas the 2-amino benzimid-azole NH binds to the side chain of E898, which is also forming
the usual salt bridge to the catalytic K882. The 2,4-difluorophenyl
moiety is believed to fill the kinase back pocket, making close
hydrophobic contacts to theC-helix, e.g., with L902. Importantly,
the 4-methyl group of the benzimidazole was designed to
interact in van der Waals distance with the side chain of L983
and the backbone of G993. G993 is the so-called pre-DFGCancer Cell 28, 29–41, July 13, 2015 ª2015 Elsevier Inc. 31
residue, which is highly variable among protein kinases (Cesar-
man, 2013). Around 85% of all protein kinases have a residue
sterically larger than glycine in the pre-DFG position. Therefore,
the 4-methyl substituent of the benzimidazole is likely to be
responsible for the improved kinase selectivity of CHZ868
(e.g., compared to BBT594) by causing steric clashes in the
binding pocket of kinases with pre-DFG residues larger than
glycine.
Activity of CHZ868 in Ba/F3 Cell-Based Models of
JAK2-Dependent B-ALL
Next, we set out to characterize the type II inhibitors CHZ868 and
BBT594, as compared to the type I JAK2 inhibitors BSK805 and
BVB808, in Ba/F3 cell-based models of oncogenic signaling in
B-ALL. All compounds potently inhibited the growth of Ba/F3-
CRLF2/IL7R cells expressing the gain-of-function mutants
CRLF2 F232C, IL7R S185C, or JAK2 R683G (Figure 1D).
CHZ868 was also highly active in Ba/F3 cells expressing TEL-
JAK2 (Figure 1B). The growth of CRLF2 and IL7R expressing
Ba/F3 cells cultured in the presence of TSLP (1 nM) was less
potently inhibited by both type I and type II inhibitors. As we
previously described (Weigert et al., 2012), treatment of Ba/F3-
CRLF2/JAK2 R683G cells with type I JAK2 inhibitors induced
hyperphosphorylation of JAK2. In contrast, CHZ868 completely
abrogated pJAK2 and pSTAT5, with downregulation of the
STAT5 target c-Myc (Figure 1E).
Discovery of a JAK2 L884P Mutation that Confers
Resistance to Type II JAK2 Inhibitors
The ability of type II inhibitors to avoid JAK2 hyperphosphoryla-
tion raised the possibility that resistance to type II inhibitors will
occur through genetic, rather than posttranslational, mecha-
nisms. To identify mutations in JAK2 that confer resistance to
type II inhibitors, Ba/F3-CRLF2 cells were transduced with a
library of JAK2 R683G that was propagated in DNA repair-defi-
cient bacteria. Clones were selected in 96-well plates in the
absence of cytokines and the presence of either 3 mM BBT594
or 3 mMCHZ868 (Figure 2A). This approach allows for the parallel
identification of multiple different alleles that confer resistance to
each inhibitor. Over 30 individual clones were recovered after se-
lection in the presence of BBT594, but nonewere recovered after
selection with CHZ868. Remarkably, all BBT594-resistant
clones harbored the same JAK2 L884Pmutation. In comparison,
a previous study using a mutagenized library of BCR-ABL in
Ba/F3 cells identified over 100 different alleles that confer resis-
tance to imatinib in vitro (Azam et al., 2003).
To confirm that JAK2 L884P is a bona fide resistance allele,
we expressed JAK2 R683G/L884P in Ba/F3-CRLF2 cells.
While the L884P allele had minimal effects on sensitivity to
BSK805 or BVB808, the IC50 for cells expressing R683G with
L884P was increased approximately 11-fold for BBT594 (Fig-
ure 2B). The L884P mutation only induced a 4-fold increase in
the IC50 value for CHZ868, potentially explaining the absence
of CHZ868-resistant clones in the mutagenesis screen. The
L884P mutation abrogated the suppressive effects of BBT594
and CHZ868 on pJAK2, pSTAT5, and c-Myc at concentrations
up to 200 nM of each drug (Figure 2C). Interestingly, in the setting
of JAK2 V617F, the L884P mutation led to only 2- to 3-fold
increased IC50 values for BBT594 and CHZ868 (Figure 2B).32 Cancer Cell 28, 29–41, July 13, 2015 ª2015 Elsevier Inc.In the X-ray crystallographic structure of JAK2 in complex with
BBT594 (Andraos et al., 2012), L884 is located at the end of the
b3 strand in the N-terminal lobe and seems to play an important
role in stabilizing the position of the C-helix, e.g., through interac-
tion with F895 (Figure 2D). Substitution of leucine with proline
may alter the conformation and flexibility of the loop linking the
b3 strand to the C-helix. This effect and the loss of interaction
with the side chain of F895 are likely to impact the position of
the C-helix and thus the shape of the back pocket. Since hydro-
phobic contacts to the side chains of I901, L902, and L905 and
the H-bond to the side chain of E898 are key interactions be-
tween the C-helix and BBT594 (Figure 2D), a different conforma-
tion of the C-helix is expected to negatively impact the binding of
type II inhibitors.
In addition, the X-ray structure revealed a hydrophobic con-
tact between the L884 and P-loop F860 side chains (Figure 2D).
This interaction contributes to the stabilization of the P-loop
when the F995 and L997 side chains are deeply buried in the
ATP binding site, as generally observed in DFG-out or type II
conformations. The loss of the favorable L884/F860 interaction
through a L884P mutation would be predicted to destabilize
the P-loop, favoring a DFG-in or type I conformation of the
kinase. In fact, L884P was previously reported in two B-ALL
cases that lack additional JAK2 mutations, suggesting that it is
an activating allele (O.S. Torra et al., 2010, Am. Soc. Hematol.,
abstract). We confirmed that L884P is an activating allele, as
Ba/F3-CRLF2/IL7Ra cells expressing JAK2 L884P proliferated
in the absence of cytokines (Figure 2E). We also noted that
JAK2 L884P is homologous to the activating EGFR L747P inser-
tional mutations observed in non-small-cell lung cancer (Fig-
ure 2F) (He et al., 2012).
CHZ868 Targets JAK2 Signaling in HumanB-ALL In Vitro
and In Vivo
To expand on the Ba/F3 model findings, we assessed type I and
type II JAK2 inhibitors using the human CRLF2-rearranged
B-ALL cell line MHH-CALL4. In addition to an IGH@-CRLF2
fusion, MHH-CALL4 cells harbor a JAK2 I682F mutation and
have constitutive phosphorylation of JAK2 and STAT5 (Russell
et al., 2009). We previously reported that MHH-CALL4 cells are
insensitive to the type I JAK2 inhibitors BVB808, BSK805, JAK
inhibitor I, ruxolitinib, and tofacitinib, with IC50 values exceeding
6–30 mM (Weigert et al., 2012).
Consistent with our prior studies, MHH-CALL4 cells were re-
fractory to BVB808 and BSK805 with IC50 values exceeding
2 mM. In contrast to the type I inhibitors, BBT594 and CHZ868
both potently suppressed growth of MHH-CALL4 cells with
IC50 values in the range of 100 nM (Figure 3A). Treatment of
MHH-CALL4 cells with 1 mM BVB808, BSK805, or ruxolitinib re-
sulted in hyperphosphorylation of the JAK2 activation loop, while
1 mM of BBT594 or CHZ868 suppressed JAK2 phosphorylation
(Figure 3B).
To expand on the findings from MHH-CALL4 cells, we estab-
lished a panel of CRLF2-rearranged B-ALL patient-derived
xenograft (PDX) models in NOD.SCID.Il2rg/ (NSG) mice that
included cases with JAK2 mutation, CRLF2 F232C, or no muta-
tion in CRLF2, IL7R, JAK1, or JAK2 (Figure S2A; Table S2). First,
we assessed the utility of ‘‘dynamic BH3 profiling’’ as a pre-
dictive biomarker for in vivo response to CHZ868 (Montero
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replicates from a representative experiment. Error bars represent SEM.
(F) Homology of JAK2 L884P to EGFR L747P insertional mutations described in non-small-cell lung cancer (He et al., 2012).et al., 2015). To this end, leukemia cells isolated from animals
engrafted with three different CRLF2-rearranged PDXs as well
as an MLL-rearranged PDX were treated ex vivo with vehicle
or CHZ868 for 16 hr and then exposed to varying concentra-
tions of the pro-apoptotic peptide BIM. Compared to vehicle
treatment, CHZ868 treatment of CRLF2-rearranged PDX cells
significantly increased cytochrome C release upon exposureto BIM peptide (Figure 3C). These data suggest specificity
of CHZ868 in targeting JAK2 dependence and predict that
JAK2-dependent PDXs are selectively ‘‘primed’’ to undergo
apoptosis through the mitochondrial pathway upon exposure
to CHZ868.
Like in MHH-CALL4 cells, 1 mM CHZ868 or BBT594 consis-
tently blocked proliferation and induced apoptosis ex vivo inCancer Cell 28, 29–41, July 13, 2015 ª2015 Elsevier Inc. 33
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treated ex vivo with vehicle or 300 nM CHZ868 for 16 hr and then exposed to 0.03 to 10 mM concentrations of synthetic pro-apoptotic BIM peptide. Change in %
cytochrome C released for CHZ868-treated samples relative to vehicle-treated samples was quantified using flow cytometry. Plotted is the maximal response
observed and averaged across three technical replicates. **p < 0.01, ***p < 0.001.
(D) Proliferation relative to DMSO-treated cells and the percentage of Annexin V-positive (AV+) cells are shown for B-ALL-X2 cells treated for 48 hr.
(E) Color-coded heatmap of the 100 most downregulated genes in splenocytes collected from mice injected with PDXs and treated with CHZ868 30 mg/kg/day
for 3 days compared to vehicle-treated controls. The same 100 genes are displayed for MHH-CALL4 cells treated with CHZ868 compared to vehicle-treated
controls.
(F) Mice engrafted with PDXs received vehicle or CHZ868 30 mg/kg/day for 6 days. Representative examples of H&E staining and IHC from spleens of mice
injected with B-ALL-X1 PDX are shown (scale bar, 100 mm).
(G) Overall survival of mice combining all 4 PDXs (n = 2 mice/PDX/arm).
All error bars in this figure indicate SEM. See also Figure S2 and Tables S2, S3, and S4.
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CRLF2-rearranged PDXs that do (B-ALL-X2, B-ALL-X3) or do not
(B-ALL-X4, B-ALL-X6) have activating JAK2 mutations (Figures
3D, S2B, and S2C). Again, ruxolitinib had little or no effect.
To gain insight into the transcriptional consequences of JAK2
inhibition by CHZ868 in vivo, we transplantedCRLF2-rearranged
B-ALLPDXs into additional NSG recipients and randomizedmice
to receive either CHZ868 30 mg/kg/day or vehicle upon >2%
peripheral blood involvement. Gene expression profiling of
splenocytes isolated after 3 days of treatment identified the top
100 genes downregulated in the 3 PDXs after treatment with
CHZ868 (Figure 3E; Table S3). This 100-gene signature was
recapitulated in MHH-CALL4 cells treated with CHZ868 (Fig-
ure 3E), indicating that a similar pattern of expression changes
is induced across models in vitro and in vivo. We noted multiple
genes involved in cell-cycle regulation, including MYC (third-
most downregulated gene), in the signature. We queried multiple
functionally defined gene sets of either MYC or E2F1 using gene
set enrichment analyses (Monti et al., 2012), which revealed that
four out of four E2F1 and seven out of sevenMYC functional gene
sets were highly enriched among the genes downregulated by
CHZ868 treatment of both the PDXs and MHH-CALL4 cells (Fig-
ure S2D; Table S4; FDR < 0.001).
We then treated an expanded cohort of four CRLF2-rear-
ranged B-ALL PDXs. Mice sacrificed after 6 days of treatment
with CHZ868 had reduced splenomegaly and lower peripheral
WBC counts compared to control animals (Figure S2E). Spleens
frommice treated with CHZ868 for 6 days had persistent infiltra-
tion with human CD45 (hCD45)-positive B-ALL cells, but almost
complete loss of pSTAT5 (Figure 3F). After 25 days of treatment,
mice receiving CHZ868 had markedly improved overall survival
compared to control animals (Figure 3G).
CHZ868 Synergizes with Dexamethasone in B-ALL Cells
In Vitro and In Vivo
To further improve on preclinical efficacy, we set out to identify
CHZ868 combination partners that would act synergistically
to kill CRLF2-rearranged B-ALLs. CHZ868 was screened in
MHH-CALL4 cells for synergy with standard-of-care B-ALL
chemotherapies, such as doxorubicin, cytarabine, vincristine,
and dexamethasone. The most notable synergy was seen be-
tween dexamethasone and CHZ868 (Figure 4A), while the
other drugs were either additive or synergistic (Figure S3A).
Similar results were obtained in CRLF2-rearranged PDXs (Fig-
ures S3B and S3C). Thus, the combination of CHZ868 and
dexamethasone may be an attractive therapeutic strategy,
perhaps analogous to the finding that the vast majority of
patients with BCR-ABL-rearranged B-ALL will achieve a com-
plete remission upon treatment with the combination of a type
II ABL inhibitor and a glucocorticoid such as dexamethasone
(Foa` et al., 2011).
Treatment of MHH-CALL4 cells with CHZ868 (300 nM) and
dexamethasone (5 nM) in combination reduced cell proliferation
(Figure 4B) and increased the percentage of cells undergoing
apoptosis (Figure 4C). Cells treated with the combination had
further reductions in pSTAT5 and c-Myc compared to cells
treated with CHZ868 alone, and this was associated with
increased PARP1 cleavage, a marker of apoptosis (Figure 4D).
Dynamic BH3 profiling revealed that upon exposure to 0.1 mM
BIM peptide, MHH-CALL4 cells treated with CHZ868 and dexa-methasone in combination showed a 2-fold increase in cyto-
chrome C release relative to cells treated with either agent alone
(Figure 4E). In contrast, the combination did not increase cyto-
chrome C release in the JAK2-independent control cell line
Nalm 6 over dexamethasone alone. Four independent apoptosis
gene sets were highly enriched in the transcriptional signature of
MHH-CALL4 cells treated with the combination of CHZ868 and
dexamethasone compared to cells treated with CHZ866 alone
(FDR < 0.001; Figures 4F and S3D).
To study the in vivo effects of CHZ868 in an immunocompe-
tent context, we generated transgenic mice with expression
of human CRLF2 and mouse JAK2 R683G restricted to murine
B cells. We previously reported that Em-CRLF2 transgenic
mice crossed with Em-Jak2 R683G mice do not develop malig-
nancies by 18 months of age (Lane et al., 2014). We crossed
these mice or mice expressing the gain-of-function mutant
CRLF2 F232C with mice carrying additional alleles known to
contribute to B-ALL, including Pax5+/, Cdkn2a/, and the
Ts1Rhr model of trisomy 21. A subset of mice succumbed to
leukemia involving the bone marrow and spleen between 131
and 378 days of age (Figures S4A–S4C). Each leukemia was
confirmed to express CRLF2 and harbor a progenitor B-ALL
immunophenotype (CD19+CD43+CD3CD11b) by flow cytom-
etry (Figures S4A–S4C). All leukemias engrafted into secondary
transplant recipients, satisfying the Bethesda criteria for B-ALL
in mice (Morse et al., 2002).
Mice were transplanted with Em-CRLF2/Em-Jak2 R683G/
Ts1Rhr/Pax5+/ (line 2539p) B-ALL and randomized to treat-
ment with vehicle, CHZ868 30 mg/kg/day by oral gavage, dexa-
methasone 1 mg/kg/day by intraperitoneal injection, or the
combination beginning 15 days after transplant. After 5 days
of treatment, mice receiving the combination had marked
reductions in splenomegaly (Figure 5A), as well as decreased
B-ALL in the peripheral blood, spleen, and bone marrow (Fig-
ure 5B). These findings were confirmed by immunohistochem-
istry (IHC) of the spleen, which showed restoration of murine
B220+ cells in mice receiving the combination for only 5 days
and clearance of cells expressing CRLF2 or pSTAT5 (Figure 5C).
While cleaved caspase 3 was increased in spleens from
mice treated with CHZ868 alone, it was not increased in the
normal cells that occupied the spleens of mice treated with
the combination (Figure 5C). Similarly, PARP1 cleavage was
increased in the spleens of mice treated with CHZ868 alone
but reduced in the spleens of mice treated with combination
(Figure 5D), suggesting that the combination is not toxic to
normal splenocytes.
We treated additional cohorts of mice transplanted with
Em-CRLF2/Em-Jak2 R683G/Ts1Rhr/Pax5+/ B-ALL for 14 days
beginning 15 days after transplant. Both dexamethasone and
CHZ868 increased overall survival compared to vehicle treat-
ment (Figure 5E). The combination further prolonged overall
survival compared with CHZ868 or dexamethasone monother-
apy, with an improvement in median survival from 23.5 days in
vehicle-treated mice to 49 days in mice that received the combi-
nation for 14 days.
To confirm these findings in human B-ALL, we treated
CRLF2-rearranged PDXs with vehicle, CHZ868 30 mg/kg/day,
dexamethasone 1 mg/kg/day, or the combination for 5 days
after engraftment (>2% peripheral blood human CD45+). MiceCancer Cell 28, 29–41, July 13, 2015 ª2015 Elsevier Inc. 35
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Figure 4. CHZ868 Synergizes with Dexamethasone in CRLF2-Rearranged, JAK2-Dependent Human B-ALL Cells
(A) Isobologram analysis of CHZ868 and dexamethasone at multiple concentrations in MHH-CALL4 cells. Results are from a representative experiment
performed in triplicate. CI, combination index.
(B) MHH-CALL4 cells were exposed to vehicle, 300 nM CHZ868, 5 nM dexamethasone, or the combination (combo) for 48 hr. Relative cell proliferation was
measured using CellTiterGlo. Results are from 18 replicates across 3 experiments.
(C) Cells were treated as in (B) and the percentage of cells positive for Annexin V alone (AV+) or both Annexin V and Propidium Iodide (AV+/PI+) in each treatment
arm was averaged across 18 replicates from 3 independent experiments. p values are comparing the percentage of negative cells.
(D) Immunoblotting for the indicated targets performed on lysates from MHH-CALL4 cells treated with vehicle (DMSO), 300 nM CHZ868, 5 nM dexamethasone,
or the combination for 24 hr.
(E) Dynamic BH3 profiling was performed in Nalm 6 and MHH-CALL4 cells treated with vehicle, 300 nM CHZ868, 5 nM dexamethasone, or the combination for
16 hr, and then exposed to 0.1 mM BIM peptide.
(F) Gene set enrichment analysis (GSEA) plots demonstrate enrichment of indicated apoptosis gene sets in MHH-CALL4 treated with the combination of
dexamethasone and CHZ868 compared to single-agent CHZ868.
In all panels of this figure, error bars represent SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S3.dosed with the combination also demonstrated marked reduc-
tions in peripheral blood leukemia compared with vehicle (Fig-
ure 5F). The combination treatment also reduced spleen
involvement with B-ALL cells compared with vehicle, CHZ868,
or dexamethasone monotherapy (Figure 5G). The transcrip-
tional profiles of PDXs treated for 3 days in vivo with the
combination compared to CHZ868 alone were highly enriched
for all four apoptosis signatures (FDR < 0.001; Figures 5H
and S4D). Finally, the combination induced further loss of
c-Myc and cleavage of PARP1 compared to either single agent
(Figure 5I).36 Cancer Cell 28, 29–41, July 13, 2015 ª2015 Elsevier Inc.DISCUSSION
Studies using human B-ALL cells with CRLF2 rearrangements
reported that only a fraction are sensitive to type I JAK inhib-
itors, including ruxolitinib (Maude et al., 2012; Tasian et al.,
2012; Weigert et al., 2012). Treatment of CRLF2-rearranged
B-ALL cells with type I inhibitors induces JAK2 hyperphos-
phorylation that may contribute to resistance to these agents
(Weigert et al., 2012). This led us and others to pursue alter-
native strategies, such as HSP90 inhibitors (Weigert et al.,
2012) or combinations of type I JAK2 inhibitors with additional
agents (Maude et al., 2012; Tasian et al., 2012; Waibel et al.,
2013).
Approximately one-third of adult B-ALL cases harbor BCR-
ABL rearrangements, which confer a very poor prognosis
when treated with conventional chemotherapy regimens. The
introduction of type II ABL kinase inhibitors like imatinib has
dramatically changed the natural history of this disease (Foa`
et al., 2011). It has remained unclear whether patients with
JAK2-dependent B-ALLs, including those with CRLF2-rear-
rangements, could achieve the same benefit through use of a
type II JAK2 inhibitor.
Our drug discovery efforts led to the identification of CHZ868,
a type II JAK2 inhibitor that potently blocks JAK2 signaling
in vitro and in vivo. Broad kinome selectivity profiling suggested
that CHZ868 interacts with a relatively small fraction of the
kinome, including JAK2 and TYK2. However, we face the chal-
lenge that in vitro biochemical assays are predominantly based
on phosphorylated and activated kinases. Thus, the selectivity
profile obtained with type II inhibitors in biochemical assay for-
mats may not reflect the selectivity in cells.
Recent studies using conditional deletions of Jak2 in mice
have demonstrated defects in hematopoietic stem cells, as
well as erythropoiesis and thrombopoiesis (Akada et al., 2014;
Park et al., 2013). As a result, potent inhibition of JAK2 signaling
could have significant hematopoietic toxicity and proper sched-
uling of JAK2 inhibition will be essential to achieve maximal anti-
leukemic activity while maintaining tolerability. Of note, CHZ868
at a dose of 30 mg/kg/day was tolerated in NSG mice for up to
25 days and in immunocompetent mice for up to 44 days, with
essentially no effects on peripheral blood counts. The trend to-
ward elevated serum erythropoietin level in CHZ868-treated
mice suggests that wild-type mice can return to homeostasis
through physiological mechanisms. These data suggest that
CHZ868 at doses comparable to 30 mg/kg/day in mice does
not completely block JAK2 signaling in normal hematopoietic
elements. This could provide a therapeutic index compared
with JAK2-dependent leukemias that would not be present
with complete loss of JAK2 function.
JAK1 associates with IL7Ra and JAK2 with CRLF2 in the
context of the CRLF2/IL7Ra heterodimer (Sessa et al., 2013).
On the basis of findings in myeloid cells (Koppikar et al.,
2012), it is possible that TYK2 or other kinases could substitute
for JAK1 and trans-phosphorylate JAK2 in B-ALL cells as well.
This could help explain the relative insensitivity of CRLF2-rear-
ranged B-ALL cells to agents with equipotent activity against
JAK1 and JAK2 (ruxolitinib) or against all JAK family members
(JAK inhibitor I) (Weigert et al., 2012). In contrast, type II inhibi-
tion stabilizes and locks JAK2 in the inactive conformation,
preventing hyperphosphorylation and blocking downstream
signaling (Andraos et al., 2012). As shown in the accompanying
manuscript by Meyer et al. (2015) in this issue of Cancer
Cell, CHZ868 can also overcome persistent JAK2 signaling
observed upon treatment of myeloid cells with type I JAK2 in-
hibitors. Although we have not directly compared the in vivo ef-
ficacy of ruxolitinib to CHZ868, our results suggest that type II
JAK2 inhibition may be a more effective strategy to target the
broad genetic diversity of CRLF2-rearranged B-ALLs, including
those with mutations in JAK2, CRLF2, IL7Ra, and SH2B3. This
contrasts with B-ALLs that harbor JAK2 fusions, which appearto be highly sensitive to type I inhibitors (Roberts et al., 2014).
Of note, Ba/F3 cells driven by TSLP are significantly less sen-
sitive to both type I and type II inhibitors than cells dependent
on mutant JAK2, CRLF2, or IL7Ra. Thus, future studies are
needed to delineate the mechanisms that affect JAK2 inhibitor
sensitivity in both TSLP-dependent and mutant JAK2-depen-
dent contexts.
The mechanisms that mediate resistance to CHZ868 and
other type II inhibitors in vivo were not explored in our study
and remain unclear. Our in vitro resistance screen identified
only one allele (L884P) that conferred resistance upon selection
in BBT594 and none upon selection in CHZ868. This could
have resulted from the relatively high ratio of inhibitor concen-
tration to IC50 (approximately 100-fold), although our previous
screens for resistance to type I inhibitors used similar ratios
(Weigert et al., 2012). We failed to recover co-crystals of
CHZ868 in a complex with JAK2, but our binding model sug-
gests that L884P confers resistance to type II inhibitors by
changing the shape of the hydrophobic back pocket. There-
fore, the failure to recover multiple different resistance alleles
raises the intriguing possibility that few if any mutations within
JAK2 are capable of altering this pocket without disrupting
JAK2 function. Additional studies, including a comprehensive
mutation analysis of all codons in the JAK2 kinase domain,
will be necessary to confirm this possibility. The identification
of JAK2 L884P as a de novo activating mutation (O.S. Torra
et al., 2010, Am. Soc. Hematol., abstract) also indicates that
patients who are candidates for type II JAK2 inhibitors will
need to have their disease genotyped at this codon (and
possibly others) to anticipate resistance.
Our data using PDX and transgenic mouse models, gene
expression profiling, and BH3 profiling all suggest that the
combination of CHZ868 with dexamethasone leads to greater
apoptosis than either agent alone. Interrogation of the gene
expression profiling data identified significant enrichment for
apoptosis-associated gene sets but did not help clarify exactly
how apoptosis may be initiated. Both JAK2 inhibition (Watanabe
et al., 1996) and glucocorticoids (Ausserlechner et al., 2004;
Rhee et al., 1995) can suppress MYC expression in lymphoid
cells, as noted in our transgenic model. In addition, the Lock lab-
oratory recently reported a glucocorticoid receptor binding site
in a BIM intronic region that directly correlated with dexametha-
sone sensitivity in B-ALL PDX models (Jing et al., 2015). These
results together further support the hypothesis that combinato-
rial effects of CHZ868 and dexamethasone involve the modula-
tion of apoptotic networks.
In summary, CHZ868 abrogated JAK2 signaling in human
CRLF2-rearranged B-ALL cells and transgenic CRLF2/JAK2-
dependent leukemias, both in vitro and in vivo. We have also
shown that the combination of CHZ868 and dexamethasone
synergistically induced leukemia apoptosis in human CRLF2-re-
arranged cell lines and PDXs and drastically improved overall
survival in a murine B-ALL model. This combination is particu-
larly attractive, on the basis of the tolerability of dexamethasone,
the ability of dexamethasone to promote apoptosis in B-ALL
cells, and the precedent for combining tyrosine kinase inhibitors
with glucocorticoids in patients with B-ALL. These data strongly
argue for the translation of type II JAK2 inhibition in combination
with dexamethasone into human trials.Cancer Cell 28, 29–41, July 13, 2015 ª2015 Elsevier Inc. 37
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Figure 5. CHZ868 with Dexamethasone Is Highly Active against CRLF2/JAK2-Dependent Leukemias In Vivo
Sublethally irradiated wild-type mice were transplanted with Em-CRLF2/Em-Jak2 R683G/Pax5+//Ts1Rhr B-ALL. After 15 days, mice were treated with vehicle,
CHZ868 (CHZ; 30 mg/kg/day by oral gavage), dexamethasone (dex; 1 mg/kg/day intraperitoneally), or CHZ868 plus dexamethasone (combo).
(A) Spleen weight as a percentage of total body weight after 5 days of treatment (n = 3 mice/arm). A photograph of representative spleens from mice in each
treatment arm is shown. Ruler scale is in cm.
(B) Percentage of human CRLF2+/mouse CD19+ cells in the peripheral blood, spleen, and bone marrow of mice after 5 days of treatment.
(C and D) IHC (C; scale bar, 50 mm) and immunoblots (D) of spleens from mice in each treatment arm sacrificed after 5 days of treatment.
(E) Survival of mice dosed with the indicated agents from days 15–28 after injection (yellow box). Survival was compared across arms using the log-rank test.
(legend continued on next page)
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EXPERIMENTAL PROCEDURES
All continuous variables were compared using a two-sided t test or one-way
ANOVA, followed by Dunnett’s test or Tukey’s test for multiple comparisons,
and error bars in all figures represent the SEM. Survival curves were compared
using the log-rank test with GraphPad software. BSK805, BVB808, BBT594,
and CHZ868 were synthesized by Novartis. Dexamethasone, cytarabine, and
doxorubicin were purchased from Sigma-Aldrich. Vincristine was purchased
from Cayman Chemical. Ruxolitinib was purchased from SelleckChem.
Cell Lines and Random Mutagenesis
Cell lines weremaintained as previously described (Weigert et al., 2012). Ba/F3
(ATCC) cells were stably transduced with CRLF2 (MSCVpuro), IL7Ra (MSCV-
GFP), EpoR (MSCVpuro), or HA-hJAK2 (MSCVneo). JAK2 is either wild-type or
with the R683G, V617F, or L884P alteration. The mutagenesis screen was
performed as previously described (Weigert et al., 2012), except that cells
were selected in either 3 mM BBT594 or 3 mM CHZ868.
Immunoblotting
Immunoblotting was performed as previously described (Weigert et al., 2012),
with pJAK2 (#3771), pSTAT5 (#4322), c-Myc (#9402), b-actin (#4967), and
JAK2 (#3230) antibodies from Cell Signaling Technology, STAT5 antibody
(sc-835) from Santa Cruz, and a-tubulin antibody (T9026) from Sigma-Aldrich.
Flow Cytometry
Splenocytes from transgenic murine leukemia models and primary human
xenografts were prepared as previously described (Weigert et al., 2012). Cells
were incubated with antibodies on ice for 1 hr before analysis. Human CD45-
FITC (347463), CD19-PECy7 (557835), and CRLF2-PE (12-5499-42) and
mouse B220-PB (558108), CD3e-PB (55-8214), CD11b-FITC (11-0112-82),
CD19-PerCPCy5.5 (45-0193-82), and CD43-APC (560663) antibodies were
purchased from eBioscience. Apoptosis was quantified using Annexin
V-FITC (Life Technologies, A13199) and Propidium Iodide (Roche Applied
Science, 11348639001). All samples were analyzed on a BD FACSCanto II
flow cytometer. Data were analyzed using FlowJo Version 9.5 (TreeStar).
In Vitro Inhibitor Assays
Cell viability assays were performed as previously described (Weigert et al.,
2012). Cells were plated at a density of 0.1 3 106 cells/ml (Ba/F3), 0.3 3 106
cells/ml (MHH-CALL4), or 0.6 3 106 cells/ml (PDXs) followed by addition of
inhibitors or vehicle (DMSO). Media for PDX cells were supplemented with
human cytokines (IL3, IL7, SCF, and Flt3L at 10 ng/ml, Peprotech), and 2-Mer-
captoethanol (2 ml in 500 ml, Sigma-Aldrich). After 48 hr (Ba/F3 cells) or 72 hr
(MHH-CALL4 and PDX cells), CellTiter-Glo Luminescent Cell Viability Assay
(Promega) was added (10 ml undiluted or 25 ml of a 1:2 dilution in each well)
and plates were read by the 2104 EnVision Multilabel Reader (PerkinElmer)
or SpectraMax M3 Microplate Reader.
Each data point was quantified in triplicate or quadruplicate and cell line ex-
periments were repeated at least twice. Analysis of pairwise dose-response
data and isobologram plots was done according to themedian-effect principle
of Chou and Talalay (CalcuSyn Software). Dose response curves and plots
were generated with GraphPad Prism software. Synergy experiments were
performed in triplicate. Combination indices were calculated using CalcuSyn
Software (Biosoft).
The JAK2 biochemical kinase assay was carried out in Caliper format with
the predominantly activated (phosphorylated) kinase domain (amino acids
808–1132). Inhibition of erythropoietin-induced STAT5 nuclear translocation
was assessed in U2OS cells that were stably transfected with the erythropoi-(F) Upon engraftment of CRLF2-rearranged B-ALL PDXs (>2% peripheral blo
Normalized peripheral blood blast count (WBC count 3%CD45+/CD19+ cells) r
each treatment condition.
(G) Spleen weight as a percentage of total body weight is shown. Horizontal
representative spleens from mice in each treatment arm is shown. The ruler pict
(H) GSEA plots demonstrate enrichment of indicated apoptosis gene sets in PDX
(I) Representative immunoblotting of spleen lysates from B-ALL-X1 treated in viv
In all panels of this figure, error bars represent SEM. *p < 0.05, **p < 0.01, ***p <etin receptor and STAT5-GFP to enable imaging of cytoplasmic and nuclear
levels of the transcription factor using the Cellomics automated imager. BH3
profiling was performed as previously described (Montero et al., 2015; Pan
et al., 2014).
Murine Experiments
De-identified human blood or bone marrow samples were obtained
with informed consent under DFCI IRB-approved protocols #05-001 and
#01-206. Xenografts were generated under DFCI IRB-approved protocol
#13-351. All xenograft and transgenic animal studies were performed under
DFCI IACUC approved protocol #13-034 and DFCI animal welfare assurance
#A3023-01. Primary human B-ALLs (P0 or greater) were xenotransplanted into
6-week old NOD.SCID.IL2Rg/ (NSG) mice, as previously described (Weigert
et al., 2012). Pharmacodynamic efficacy was assessed in mice 2 hr after the
last dose. Immunohistochemistry was performed as previously described
(Weigert et al., 2012; Baffert et al., 2010).
Gene Expression Profiling, Marker Selection, and Gene Set
Enrichment Analysis
MHH-CALL4 cells cultured at 1 3 106 cells/ml were treated with vehicle
(DMSO), CHZ868 (500 nM), dexamethasone (250 nM), or the combination
for 12 hr. The experiment was performed in triplicate. Primary human xeno-
grafts B-ALL-X1, -X2, and -X3 were treated in vivo with vehicle, CHZ868
(30 mg/kg/day orally), dexamethasone (1 mg/kg/day intraperitoneally), or the
combination for 3 days and then sacrificed 2 hr after the last dose. Total
RNA was extracted from MHH-CALL4 cells and unselected splenocytes of
the PDXs using Trizol followed by purification on an RNeasy column (QIAGEN).
RNA quality and concentrationwere confirmed by PicoGreen and profiling was
performed on an Affymetrix human HTA-2_0 gene chip in the Dana-Farber
Microarray Core (http://macf-web.dfci.harvard.edu).
Additional experimental details are available in the Supplemental
Information.
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